NRX Pharmaceuticals (NRXP) Operating Income (2017 - 2026)
NRX Pharmaceuticals (NRXP) posted quarterly Operating Income of -$4.7 million for Q1 2026, down 23.26% year-over-year from -$6.2 million in Q1 2025, and down 2.55% quarter-over-quarter from -$4.6 million in Q4 2025.
NRX Pharmaceuticals (NRXP) Operating Income (2017 - 2026) Analysis & Trends
NRX Pharmaceuticals (NRXP) has reported Operating Income for 10 consecutive years, with -$4.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Income fell 23.26% year-over-year to -$4.7 million; the TTM figure through Mar 2026 stood at -$17.1 million (down 4.7% YoY), while the FY2025 annual figure was -$16.2 million, up 12.31% from the prior year.
- Operating Income declined to -$4.7 million in Q1 2026 per NRXP's latest filing, from -$4.6 million in the prior quarter.
- Across five years, Operating Income topped out at -$2.4 million in Q4 2024 and bottomed at -$15.7 million in Q1 2022.
- Historically, Operating Income has averaged -$6.2 million across 5 years, with a median of -$4.7 million in 2026.
- Annual changes were most pronounced in 2022 — Operating Income surged 81.33% — and 2025, when it sank 90.13%.
- NRX Pharmaceuticals' Operating Income stood at -$9.9 million in 2022, then jumped by 55.44% to -$4.4 million in 2023, then surged by 44.8% to -$2.4 million in 2024, then tumbled by 90.13% to -$4.6 million in 2025, then fell by 2.55% to -$4.7 million in 2026.
- Business Quant data shows NRXP's Operating Income at -$4.7 million in Q1 2026, -$4.6 million in Q4 2025, and -$4.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 133.12 Mn |
| 10 | NRX Pharmaceuticals | 132.53 Mn | 105.83 Mn | 426,000.00 | -6.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.74 Mn |
| Dec 31, 2025 | -4.62 Mn |
| Sep 30, 2025 | -4.02 Mn |
| Jun 30, 2025 | -3.73 Mn |
| Mar 31, 2025 | -3.85 Mn |
| Dec 31, 2024 | -2.43 Mn |
| Sep 30, 2024 | -3.02 Mn |
| Jun 30, 2024 | -7.05 Mn |
| Mar 31, 2024 | -6.00 Mn |
| Dec 31, 2023 | -4.41 Mn |
| Sep 30, 2023 | -5.81 Mn |
| Jun 30, 2023 | -8.19 Mn |
| Mar 31, 2023 | -3.85 Mn |
| Dec 31, 2022 | -9.89 Mn |
| Sep 30, 2022 | -9.14 Mn |
| Jun 30, 2022 | -9.60 Mn |
| Mar 31, 2022 | -15.71 Mn |
| Dec 31, 2021 | -52.98 Mn |
| Sep 30, 2021 | -20.10 Mn |
| Jun 30, 2021 | -17.12 Mn |